<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Materials Science and Engineering</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FF4970EE-DB0A-48FA-9C87-BB6C90D7D47B"><gtr:id>FF4970EE-DB0A-48FA-9C87-BB6C90D7D47B</gtr:id><gtr:firstName>Aneurin</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Kennerley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3406FFA-68B6-49BB-A34C-5A9008DA9B5A"><gtr:id>E3406FFA-68B6-49BB-A34C-5A9008DA9B5A</gtr:id><gtr:firstName>Pamela</gtr:firstName><gtr:otherNames>Jean</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B0000E7C-2E34-416B-A2A9-9DD3D290D73D"><gtr:id>B0000E7C-2E34-416B-A2A9-9DD3D290D73D</gtr:id><gtr:firstName>Giuseppe</gtr:firstName><gtr:surname>Battaglia</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C7224E62-7F03-4084-9546-2E328EBFC73C"><gtr:id>C7224E62-7F03-4084-9546-2E328EBFC73C</gtr:id><gtr:firstName>Ramin</gtr:firstName><gtr:surname>Golestanian</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/45F8017A-5521-456E-A457-23319A5AF4F0"><gtr:id>45F8017A-5521-456E-A457-23319A5AF4F0</gtr:id><gtr:firstName>Dawn</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/980AF85C-45AF-47A0-A294-2218A78D2ACB"><gtr:id>980AF85C-45AF-47A0-A294-2218A78D2ACB</gtr:id><gtr:firstName>Richard James</gtr:firstName><gtr:surname>Mead</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/322B0287-D86B-44B3-9A53-10FFA0F9C9DF"><gtr:id>322B0287-D86B-44B3-9A53-10FFA0F9C9DF</gtr:id><gtr:firstName>Ke</gtr:firstName><gtr:surname>Ning</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A260BA3D-B7C9-4458-8D9D-0E9A14F2B344"><gtr:id>A260BA3D-B7C9-4458-8D9D-0E9A14F2B344</gtr:id><gtr:firstName>Rodney</gtr:firstName><gtr:otherNames>Harris</gtr:otherNames><gtr:surname>Smallwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0CE0885F-32B3-491A-9BA0-32EED50E92AC"><gtr:id>0CE0885F-32B3-491A-9BA0-32EED50E92AC</gtr:id><gtr:firstName>Oliver</gtr:firstName><gtr:surname>Bandmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168C68A5-8E83-4C78-B8A8-42225E052B7E"><gtr:id>168C68A5-8E83-4C78-B8A8-42225E052B7E</gtr:id><gtr:firstName>Ying</gtr:firstName><gtr:surname>Zheng</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D96679F-7B87-4095-8643-EDEC89A16D03"><gtr:id>6D96679F-7B87-4095-8643-EDEC89A16D03</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Geoffrey</gtr:otherNames><gtr:surname>Ince</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2C82C38D-B8D5-41CF-87A9-1AD9A28DEC88"><gtr:id>2C82C38D-B8D5-41CF-87A9-1AD9A28DEC88</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Armes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3545C5E0-FEB8-4ADD-A14D-7A80DC781777"><gtr:id>3545C5E0-FEB8-4ADD-A14D-7A80DC781777</gtr:id><gtr:firstName>Rod</gtr:firstName><gtr:surname>Hose</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CA018A50-1076-4606-ACEE-E2BA6804DB53"><gtr:id>CA018A50-1076-4606-ACEE-E2BA6804DB53</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Ryan</gtr:surname><gtr:orcidId>0000-0001-7737-0526</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F7BF55C1-D08C-44E6-B66D-DAE7B73E9820"><gtr:id>F7BF55C1-D08C-44E6-B66D-DAE7B73E9820</gtr:id><gtr:firstName>Mimoun</gtr:firstName><gtr:surname>Azzouz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BFB806F6-DDBB-471B-876E-3BEB77328E09"><gtr:id>BFB806F6-DDBB-471B-876E-3BEB77328E09</gtr:id><gtr:firstName>Myles</gtr:firstName><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/994B9212-3116-439A-B3E1-59B16A4FC5D1"><gtr:id>994B9212-3116-439A-B3E1-59B16A4FC5D1</gtr:id><gtr:firstName>Jason</gtr:firstName><gtr:surname>Berwick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG062137%2F1"><gtr:id>BA1AA0F8-4D3B-40A5-A657-28C1781788A4</gtr:id><gtr:title>Engineering Virus-like Nanoparticles for Targeting the Central Nervous System</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G062137/1</gtr:grantReference><gtr:abstractText>Despite vast efforts that have been made to develop novel strategies to overcome obstacles, the delivery of any therapeutic agents to central nervous system (CNS) is still a major challenge. This must be overcome to develop fully effective treatments for conditions affecting it, from dementia to motor disorders. The most limiting factors to deliver therapeutic agents to the CNS are the barriers that protect it: the blood brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). We seek to use polymer nanotechnology to engineer biocompatible and nanometer-sized vectors that are able to pass through different extracellular and biological barriers, opening up the possibility of selectively targeting potentially effective treatments to where they are needed. We will combine recent advances in both polymer nanotechnology and neuroscience implementing experimental design and biological evaluation with whole body imaging techniques and modelling approaches. Targeted delivery of therapeutic agents direct into the CNS has the potential to cut down on debilitating side effects associated with current treatments and minimize neuronal damage in CNS degenerative disorders, both of which have major implications for life long health and well being for both patients and carers. Our long term aim is to demonstrate the potential of this technology in the clinic using the example of motor neuron disease where members of the team have excellent combined scientific and clinical expertise. We plan to interface Chemistry, Physics, Bioengineering with Clinical Neuroscience and Neurology. This will allow the bridging of novel scientific discoveries into real world medical applications through rigorous engineering characterization. This is a very challenging and strategic project. Yet, achieving the objectives presented would be very valuable in validating a novel biomedical delivery system ready for clinical studies with the potential to effectively treat several neurological disorders. In the first 2 years will focus our effort on two specific exemplar disorders. Therapies which show efficacy in those could potentially be extended for other common neurological disorders such as Parkinson's and Alzheimer's diseases. By the end of the three years, we aim to identify at least one delivery mechanism that has efficacy data for one disease/target in a preclinical model. In order to realize this effectively we will engage with patient groups and the general public throughout the process, stimulating interest, managing expectations, addressing ethical and safety concerns and the regulatory agenda. So as to facilitate any potential clinical evaluation we also aim to engage from the early stages of the programme with the Medicines and Healthcare products Regulatory Agency (MHRA), and clinicians and patient groups. Finally we will liaise with technology transfer and business managers and integrate the multidisciplinary training including companies that have already established collaborations with our team such as: Biocompatibles Ltd, Oxford BioMedica Ltd, GlaxoSmithKline, and UCB Pharma.</gtr:abstractText><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2125910</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>This work has now allowed us to become one of the group very active in drug delivery to the CNS</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>492D578C-DDC8-42F7-BAF5-AEF4927246DB</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54648fb00cc061.65286250</gtr:outcomeId><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>JE-s form includes all the outcomes</gtr:description><gtr:exploitationPathways>Our papers published out of these work have been highly cited. Several groups are now adopting the same strategy to engineering nanoparticles</gtr:exploitationPathways><gtr:id>798BB908-6561-412F-A314-A1EDF8453F69</gtr:id><gtr:outcomeId>54648ed9dead37.89201010</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FFAA6B1E-0ECE-4D17-8C7E-A6181AF9E40E</gtr:id><gtr:title>Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f100240e7a98a6cb8824705c2f845d6"><gtr:id>2f100240e7a98a6cb8824705c2f845d6</gtr:id><gtr:otherNames>Mead RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5464a234631b18.65019768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>284DECD3-08DC-47E2-8CE7-9841A42DFAC4</gtr:id><gtr:title>Encapsulation of biomacromolecules within polymersomes by electroporation.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>5464a1709b59e7.90928996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE49ED32-17AD-4D07-BABD-C275A65639CE</gtr:id><gtr:title>Inspired by nature: fundamentals in nanotechnology design to overcome biological barriers.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aad51a9a1f52ef61ee5fa590c1b86f77"><gtr:id>aad51a9a1f52ef61ee5fa590c1b86f77</gtr:id><gtr:otherNames>Avila-Olias M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn><gtr:outcomeId>5464a1713e2296.21560265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>335A009A-7A49-4DE5-BB42-384E814E0AE0</gtr:id><gtr:title>Polymersome production on a microfluidic platform using pH sensitive block copolymers.</gtr:title><gtr:parentPublicationTitle>Lab on a chip</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c738ae71179b28fa04d561db817e9fe2"><gtr:id>c738ae71179b28fa04d561db817e9fe2</gtr:id><gtr:otherNames>Brown L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-0189</gtr:issn><gtr:outcomeId>5464a16eecbe58.38788564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9760265-62EA-4C1A-A98A-0598EA7F883B</gtr:id><gtr:title>Cellular interactions with photo-cross-linked and pH-sensitive polymersomes: biocompatibility and uptake studies.</gtr:title><gtr:parentPublicationTitle>Biomacromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b237801a0e62f44b00a3f3bcd57768c"><gtr:id>0b237801a0e62f44b00a3f3bcd57768c</gtr:id><gtr:otherNames>Gaitzsch J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-7797</gtr:issn><gtr:outcomeId>5464a170e11137.93788607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>332C5191-0F3C-43E6-B338-2E01508CFB32</gtr:id><gtr:title>Nanoscale detection of metal-labeled copolymers in patchy polymersomes</gtr:title><gtr:parentPublicationTitle>Polymer Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c421484325aba8bb57ea4bab88036c37"><gtr:id>c421484325aba8bb57ea4bab88036c37</gtr:id><gtr:otherNames>Ruiz-P?rez L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5675fc8938153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D9DB399-0FDE-42BE-8561-41A05B85F621</gtr:id><gtr:title>Abnormalities in whisking behaviour are associated with lesions in brain stem nuclei in a mouse model of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Behavioural brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/749357073c47be483d58d20722ab8f90"><gtr:id>749357073c47be483d58d20722ab8f90</gtr:id><gtr:otherNames>Grant RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-4328</gtr:issn><gtr:outcomeId>5675d930daa76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35E934E0-F307-4D64-B859-09FBA24453D2</gtr:id><gtr:title>Controlling polymersome surface topology at the nanoscale by membrane confined polymer/polymer phase separation.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58e00a99419379ac36c69cab523ac329"><gtr:id>58e00a99419379ac36c69cab523ac329</gtr:id><gtr:otherNames>LoPresti C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>doi_55f95a95af0c58e6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94C7E967-0201-4D4A-94CB-6B47BBE9C97B</gtr:id><gtr:title>Nile Blue-based nanosized pH sensors for simultaneous far-red and near-infrared live bioimaging.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fef47854e58eb3013f9aca5dc3e145ba"><gtr:id>fef47854e58eb3013f9aca5dc3e145ba</gtr:id><gtr:otherNames>Madsen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>5464a171d28384.35730589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D218497-8D0A-41BB-A2CB-67E8EEC1A638</gtr:id><gtr:title>LRP-1-mediated intracellular antibody delivery to the Central Nervous System.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15f7538f139150062a0198cf42183fa9"><gtr:id>15f7538f139150062a0198cf42183fa9</gtr:id><gtr:otherNames>Tian X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675e8cacddbd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B190756D-2E05-41F8-A1C8-AA721FB41992</gtr:id><gtr:title>pH-sensitive tubular polymersomes: formation and applications in cellular delivery.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87e25cc266a9c387998b844466f00b45"><gtr:id>87e25cc266a9c387998b844466f00b45</gtr:id><gtr:otherNames>Robertson JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>5464a1723a4af8.20644707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF1B7A3F-0607-4807-A34E-4210A6F42B45</gtr:id><gtr:title>In situ formation of magnetopolymersomes via electroporation for MRI.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f432864b58644f0ff90834e692e09ca"><gtr:id>3f432864b58644f0ff90834e692e09ca</gtr:id><gtr:otherNames>Bain J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c788d652b889.50544385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A608DA6E-0583-424B-BC18-0239C8DA162E</gtr:id><gtr:title>Live cell imaging of membrane/cytoskeleton interactions and membrane topology.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cba44ac7419694f4f35044392d59aee4"><gtr:id>cba44ac7419694f4f35044392d59aee4</gtr:id><gtr:otherNames>Chierico L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5464a1725eab82.66672885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A332D441-853C-4C24-9938-B830AB98DBD5</gtr:id><gtr:title>Tracking nanoparticles in three-dimensional tissue-engineered models using confocal laser scanning microscopy.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c289f5bd53fdaa5504ea11435fb55646"><gtr:id>c289f5bd53fdaa5504ea11435fb55646</gtr:id><gtr:otherNames>Hearnden V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5464a16f69f3d7.41761924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D10C8906-1FAB-4DA0-8959-DDF84FA2FFB9</gtr:id><gtr:title>Translocation of flexible polymersomes across pores at the nanoscale.</gtr:title><gtr:parentPublicationTitle>Biomaterials science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f73c7ff3f85da471cd76deaf7cea66e"><gtr:id>6f73c7ff3f85da471cd76deaf7cea66e</gtr:id><gtr:otherNames>Pegoraro C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2047-4830</gtr:issn><gtr:outcomeId>58c788d6aca079.59061497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AC4DCD7-E489-4B20-B3E5-332A6F2B98E9</gtr:id><gtr:title>Modelling the Transport of Nanoparticles under Blood Flow using an Agent-based Approach.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/480e1c01beb4f967839433869384cc1c"><gtr:id>480e1c01beb4f967839433869384cc1c</gtr:id><gtr:otherNames>Fullstone G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c788d5eb1486.50519345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D727621-A7D6-4AA0-8BA9-DC4FD6998987</gtr:id><gtr:title>Exploiting endocytosis for nanomedicines.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f08f1aa10bda9c921ebeac5b14f967d"><gtr:id>9f08f1aa10bda9c921ebeac5b14f967d</gtr:id><gtr:otherNames>Akinc A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1943-0264</gtr:issn><gtr:outcomeId>58c788d713f817.49440706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A010244-1B36-48BA-983D-DF38491FCAA9</gtr:id><gtr:title>Rescue of mitochondrial function in parkin-mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes.</gtr:title><gtr:parentPublicationTitle>Neuroscience letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e282f7b29493f01eff40394c7080961"><gtr:id>5e282f7b29493f01eff40394c7080961</gtr:id><gtr:otherNames>Yealland G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0304-3940</gtr:issn><gtr:outcomeId>58c78bcf3da282.76825967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>242C0F25-D535-4B2D-A78B-67EF16014B85</gtr:id><gtr:title>Pericytes from Mesenchymal Stem Cells as a model for the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15f7538f139150062a0198cf42183fa9"><gtr:id>15f7538f139150062a0198cf42183fa9</gtr:id><gtr:otherNames>Tian X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c787868d93e0.45840949</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G062137/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>EFFEC6B1-6BC8-4C9D-9D77-02CEF5E4E301</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Biomedical neuroscience</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E48C802F-8897-4353-910A-09D09331BB82</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Medical science &amp; disease</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>